Clinical Rescue


Working together to perfect your formulation

By providing robust information on how formulations are working in vivo through the non-invasive imaging technique of gamma scintigraphy, you can uncover the reasons for clinical failure.


Alternatively, increase your chance of success first time by implementing these strategies early.



Gamma Scintigraphy











Gamma scintigraphy is a nuclear imaging technique that allows non-invasive in vivo assessment of dosage form behaviour. It can be applied to most routes of drug delivery including oral, nasal, pulmonary and ophthalmic.


Achieve real-time monitoring of dosage form behaviour by including a suitable radiolabel.


Combine scintigraphy with PK to give insight into how absorption is affected by dosage form transit and residence.



Definite Answers











Scintigraphy studies can be carried out in healthy volunteers or patient groups with a cohort size from as few as 6 individuals to show that:

      • The drug is actually being released

      • The drug is delivered at the right physiological location

      • The drug is being released at the right time


These indicators are valuable tools to begin to understand the reasons behind failure in the clinic.


We believe that no in vitro test can replace the human body as a formulation screening tool and scintigraphy allows us to do this in a quick and cost effective way.



A solution to the problem









BDD also thrives on dealing with challenging formulation issues and has a wealth of experience in various routes of drug delivery.


Using the valuable data gained from a simple scintigraphic/PK study, DDi scientists will improve on the formulation and deliver a dosage form that will have a significantly higher chance of clinical success.


Back into the clinic


With heightened confidence, you can place the improved product back into your clinical trial.

We can further assist by providing small scale GMP manufacture of IMPs for these trials.


Reduce risk of clinical failure


Utilise clinical gamma scintigraphy even before embarking on Phase I/II studies to:

      • Screen a panel of formulations prior to choosing which one to take forward into clinical trials

      • Establish accurate delivery profiles for controlled and targeted release systems

      • Demonstrate superiority over marketed competitor products


Early stage clinical formulation screening is exceptionally advantageous in terms of providing valuable data for critical decision making.


          BDD Ltd



Glasgow Royal Infirmary

84 Castle St


G4 0SF, UK


Bio-City Scotland

Bo'ness Road

Chapelhall, Newhouse


Contact Us

Clinical Site. +44 (0)141 552 8791

Formulation site. +44 (0)141 552 7752



Social Media

  • LinkedIn - White Circle
  • Twitter - White Circle
  • YouTube - White Circle
  • Facebook - White Circle

Registered in Scotland No. 212868        Privacy Policy     Acceptable Use     Terms of Use   

@2021 BDD Ltd